Sills Cummis Epstein & Gross P.C. Company Profile

17:39 EDT 19th October 2018 | BioPortfolio

Founded in 1971, Sills Cummis has established an outstanding global reputation. Our growth has been made possible by a large national client roster and an ever-expanding list of international client corporations. The Firm was featured in Chambers USA Guide to America's Leading Lawyers for Business which ranked the Real Estate Department first in New Jersey and the Corporate, Employment and Labor, and Litigation Departments in the top three in the State. Our growth continues because Sills Cummis Epstein & Gross P.C. is more than just a law firm. It is a think tank for the industries that choose us. We go beyond what is expected of a law firm by partnering with our clients and taking an insider’s view of each client’s business.On a national level, our lawyers represent companies from Fortune 500 to emerging growth. On an international level, we are frequently called upon and have been focusing on cross-border transactions with non-U.S. companies doing business in the U.S. As a full-service firm, our clients have access to all of our practice groups, thus alleviating the need to bring in other consultants when ancillary issues arise


The Legal CenterOne Riverfront Plaza
New Jersey
United States of America


Phone: (973) 643-7000
Fax: (973) 643-6500

News Articles [124 Associated News Articles listed on BioPortfolio]

Medical News Today: What to know about Epstein-Barr virus testing

The Epstein-Barr virus is a type of herpes virus. It is very common, and because the symptoms are quite general, a doctor may order an Epstein-Barr virus blood test to confirm whether or not a person ...

Epstein-Barr virus and autoimmune diseases

Researchers found a mechanism that may explain why the Epstein-Barr virus is associated with certain autoimmune illnesses such as lupus.

Researchers find STAT3 as therapeutic target for chronic active EBV infection

Tokyo Medical and Dental University study shows that ruxolitinib-induced inhibition of STAT3 activity blocks survival and reduces pro-inflammatory cytokine production in Epstein-Barr virus (EBV)-infec...

After Blockbuster Maiden Lithium Resource, How Will PEA Look?

Peter Epstein of Epstein Research speaks with the CEO of a lithium explorer that plans to release a PEA on its Nevada project soon. Investors rely on us to share promising investment ideas in a chang...

Wealth Minerals Prudently, Albeit Slowly, Advancing in Chile

Peter Epstein of Epstein Research discusses whether the lithium market is oversold and profiles one lithium company that he follows. Investors rely on us to share promising investment ideas in a chan...

Cypress Development Delivers Monster Maiden Lithium Resource

Peter Epstein of Epstein Research discusses the maiden resource estimate for a Nevada lithium project. Investors rely on us to share promising investment ideas in a changing world. Our exclusive inte...

VIDEO: Despite 'revolutionary' potential for health care, biologics remain costly, limited availability

SAN DIEGO — At the United Rheumatology National Meeting, Alan L. Epstein, MD, clinical professor of medicine at the University of Pennsylvania Perelman School of Medicine discusses the continued hig...

Lithium Explorer Cashed Up, Actively Exploring Giant Land Package in Argentina

Peter Epstein of Epstein Research profiles a lithium explorer with projects in Argentina that is actively moving to Molecular Recognition Technology for metal separation. Investors rely on us to shar...

PubMed Articles [246 Associated PubMed Articles listed on BioPortfolio]

The Effects of Epstein-Barr Virus Nuclear Antigen 2 (EBNA2) on B-Lymphocytic Activity.

Epstein-Barr virus is a worldwide disease that can cause a wide range of human diseases, the person will become a lifelong carrier of the virus once infected. To investigate the mechanism of Epstein-B...

Quality of Life in Patients with Vestibular Schwannomas Following Gross Total or Less than Gross Total Microsurgical Resection: Should We be Taking the Entire Tumor Out?

The goal of microsurgical removal of a vestibular schwannoma is to completely remove the tumor, to provide long-term durable cure. In many cases, less than gross total resection (GTR) is performed to ...

Dysregulation of Epstein-Barr virus infection in hypomorphic ZAP70 mutation.

Some patients with genetic defects develop Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (LPD)/lymphoma as the main feature. Hypomophic mutations can cause different clinical and la...

Epstein-Barr Virus Hepatitis: A Review of Clinicopathologic Features and Differential Diagnosis.

The liver is frequently affected by Epstein-Barr virus (EBV) infection, but involvement is commonly subclinical and self-limited. Severe and potentially fatal EBV hepatitis has also been occasionally ...

Porphyromonas endodontalis reactivates latent Epstein-Barr virus.

To determine whether Porphyromonas endodontalis can reactivate latent Epstein-Barr virus (EBV).

Clinical Trials [217 Associated Clinical Trials listed on BioPortfolio]

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to help the body kill cancers associated with this virus. PURPOSE: Phase I trial to study the effecti...

Immunodeficiency for Severe Epstein-Barr Virus Infection

The purpose of this study is to investigate the immune responses associated with Epstein-Barr virus infections, and to find out the possible immunodeficiencies that may be linked to severe...

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders. Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus. Phenylbutyrate may make ...

Biological Therapy in Treating Patients With Lymphoma, Lymphoproliferative Disease, or Malignancies

RATIONALE: Some types of lymphoma or lymphoproliferative disease are associated with Epstein-Barr virus. White blood cells from donors who are immune to Epstein-Barr virus may be an effect...

Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation

RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation. PURPOSE: Phase II trial to study...

Companies [34 Associated Companies listed on BioPortfolio]

Sills Cummis Epstein & Gross P.C.

Founded in 1971, Sills Cummis has established an outstanding global reputation. Our growth has been made possible by a large national client roster and an ever-expanding list of international client c...

Epstein Becker Green

Epstein Becker & Green, P.C., is a national law firm with a primary focus on health care and life sciences; employment, labor, and workforce management; and litigation and busines...

Jason Epstein

Pomerantz Haudek Grossman & Gross LLP


NRG Renew, a subsidiary of NRG Energy, Inc., owns or has partial investment in more than 150 renewable energy projects totaling approximately 4,500 gross MWac of solar and wind ca...

More Information about "Sills Cummis Epstein & Gross P.C." on BioPortfolio

We have published hundreds of Sills Cummis Epstein & Gross P.C. news stories on BioPortfolio along with dozens of Sills Cummis Epstein & Gross P.C. Clinical Trials and PubMed Articles about Sills Cummis Epstein & Gross P.C. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sills Cummis Epstein & Gross P.C. Companies in our database. You can also find out about relevant Sills Cummis Epstein & Gross P.C. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record